March 29 (Reuters) - Pfizer Inc:
* PFIZER ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ATTR-ACT STUDY OF TAFAMIDIS IN PATIENTS WITH TRANSTHYRETIN CARDIOMYOPATHY
* PFIZER INC - STUDY MET ITS PRIMARY ENDPOINT
* PFIZER INC - PRELIMINARY SAFETY DATA SHOWED THAT TAFAMIDIS WAS GENERALLY WELL TOLERATED
* PFIZER INC - PRELIMINARY SAFETY DATA SHOWED THAT TAFAMIDIS WAS GENERALLY WELL TOLERATED IN POPULATION AND NO NEW SAFETY SIGNALS WERE IDENTIFIED Source text for Eikon: Further company coverage: